174 related articles for article (PubMed ID: 35675031)
1. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
Du Y; Dai J; Mao L; Wei X; Bai X; Chen L; Lin J; Chi Z; Cui C; Sheng X; Lian B; Tang B; Wang X; Yan X; Li S; Zhou L; Guo J; Chen Y; Si L
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):93-101. PubMed ID: 37625814
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Lan CY; Zhao J; Yang F; Xiong Y; Li R; Huang Y; Wang J; Liu C; Bi XH; Jin HH; Meng J; Zhao WH; Zhang L; Wang YF; Zheng M; Huang X
Cell Rep Med; 2022 Jul; 3(7):100689. PubMed ID: 35858589
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial.
Wang ZM; Zhuang RY; Guo X; Zhang CL; You Y; Chen LS; Liu WS; Zhang Y; Luo RK; Hou YY; Lu WQ; Zhou YH
Clin Cancer Res; 2022 Dec; 28(24):5290-5296. PubMed ID: 36228149
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
Zhou J; Sun Y; Zhang W; Yuan J; Peng Z; Wang W; Gong J; Yang L; Cao Y; Zhao H; Chen C; Wang W; Shen L; Zhou A
Hepatology; 2023 Jan; 77(1):65-76. PubMed ID: 35491432
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer.
Zhang W; Wang J; Wang Q; Cheng Y; Yang L; Li Y; Zhong H; Chu T; Dong Y; Zhang Y; Qian F; Xiong L; Shi C; Zhang C; He Z; Zhu J; Liu X; Ma H; Li K; Han B
Lung Cancer; 2023 Oct; 184():107353. PubMed ID: 37647728
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
Cai M; Zhu J; Zhou G
Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
Zhang XY; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
[TBL] [Abstract][Full Text] [Related]
10. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
[TBL] [Abstract][Full Text] [Related]
12. Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy.
Zheng A; Liu J; Liu Z; Mo Z; Fu Y; Deng Y; Jiang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):58. PubMed ID: 38294686
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.
Wang J; Sun T; Ouyang Q; Han Y; Xu B
iScience; 2023 Jun; 26(6):106876. PubMed ID: 37275528
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.
Li Y; Liu Y; Qu Y; Chen X; Qu X; Ye Y; Du X; Cheng Y; Xu M; Zhang H
Front Immunol; 2022; 13():832593. PubMed ID: 35603147
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
16. Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02).
Xie L; Liang X; Xu J; Sun X; Liu K; Sun K; Li Y; Tang X; Li X; Zhan X; Niu X; Guo W
BMC Cancer; 2023 Sep; 23(1):868. PubMed ID: 37715133
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
[TBL] [Abstract][Full Text] [Related]
18. The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study.
Liu Z; Wang X; Wang J; Zhang P; Li C; Wang B; Gao S; Liu O; Yao W
Front Oncol; 2023; 13():1124517. PubMed ID: 36910639
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
20. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
